These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29259984)

  • 1. mTOR-Dependent Cell Proliferation in the Brain.
    Ryskalin L; Lazzeri G; Flaibani M; Biagioni F; Gambardella S; Frati A; Fornai F
    Biomed Res Int; 2017; 2017():7082696. PubMed ID: 29259984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
    Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
    Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
    Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
    J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
    Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
    Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of mTOR in glioblastoma.
    Duzgun Z; Eroglu Z; Biray Avci C
    Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitidine chloride inhibits the malignant behavior of human glioblastoma cells by targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Wang J; Qi Q; Huang B; Chen A; Li X; Wang J
    Oncol Rep; 2016 Oct; 36(4):2160-8. PubMed ID: 27498786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.
    Li S; Guo W; Gao Y; Liu Y
    Tumour Biol; 2015 Apr; 36(4):2607-12. PubMed ID: 25431263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
    Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
    J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
    Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
    Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the AKT pathway in glioblastoma.
    McDowell KA; Riggins GJ; Gallia GL
    Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways.
    Aeder SE; Martin PM; Soh JW; Hussaini IM
    Oncogene; 2004 Dec; 23(56):9062-9. PubMed ID: 15489897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
    Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
    Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.